This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing and Ancillary Supply
    • Direct-to-site
    • Demand Driven Labelling & Distribution
    • Investigator Initiated Trials
    • Technical Consultancy

    Information for…

    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Global offices
    Australia & New Zealand
    Japan
    Singapore
    South Africa
    United Kingdom
    United States
  • Investors
    At a Glance
    Financial Highlights
    Investment Case
    • Business Model
    • Market Overview
    • Strategy
    • Our Businesses
    Share tools
    Results, Reports and Presentations
    Quantum Archive
    Financial Calendar
    Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
    Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
    AIM Rule 26
    Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • Company
    About Clinigen >
    • History
    • Responsible business
    • Operational excellence
    • Our brands
    Careers >
    • Frequently Asked Questions
    • Apply Online
    • Privacy Notice - Applicants
    Newsroom
    • Video Library
    • Press Releases
  • Insights and Events
  • Cliniport medicine finder
Clinigen France
Clinigen Germany
Get in touch
Get in touch
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing and Ancillary Supply
      • Direct-to-site
      • Demand Driven Labelling & Distribution
      • Investigator Initiated Trials
      • Technical Consultancy
  • Global offices
    Global offices
    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Investors
    Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Market Overview
      • Strategy
      • Our Businesses
    • Share tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Company
    Company
    • About Clinigen >
      About Clinigen >

      About Clinigen >

      • History
      • Responsible business
      • Operational excellence
      • Our brands
    • Careers >
      Careers >

      Careers >

      • Frequently Asked Questions
      • Apply Online
      • Privacy Notice - Applicants
    • Newsroom
      Newsroom
      • Video Library
      • Press Releases
  • Insights and Events
  • Cliniport medicine finder
Global sites
  • Clinigen France
  • Clinigen Germany

Press Releases

  • At a Glance
  • Financial Highlights
  • Investment Case
    • Business Model
    • Market Overview
    • Strategy
    • Our Businesses
  • Share tools
  • Results, Reports and Presentations
  • Quantum Archive
  • Financial Calendar
  • Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
  • Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
  • AIM Rule 26
  • Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • 2018
  • 2017
  • 2016
  • 2015
  • Archive
More
Filter by
  • 17 Jul 2018

    Clinigen acquires global rights to Proleukin®  outside the United States
    Related materials
    PDF (204.19KB)
  • 17 Jul 2018

    Year end trading update
    Related materials
    PDF (365.71KB)
  • 14 Jun 2018

    Clinigen signs exclusive supply & distribution agreement with Lukare  for Elliotts B® Solution
    Related materials
    PDF (198.92KB)
  • 04 Jun 2018

    Future Oncology publishes dexrazoxane article supporting EC removal of restrictions for use in children and adolescents
    Related materials
    PDF (164.16KB)
  • 31 May 2018

    Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa
    Related materials
    PDF (360.96KB)
  • 24 May 2018

    Clinigen signs agreement with Nordic Pharma for aprotinin
    Related materials
    PDF (306.54KB)
  • 22 May 2018

    Clinigen and Mitsubishi Tanabe initiate European Managed Access Program for edaravone to treat ALS
    Related materials
    PDF (195.03KB)
  • 12 Apr 2018

    Clinigen receives PBS listing for TREXJECT® (methotrexate) in Australia for the treatment of rheumatoid arthritis and psoriasis
    Related materials
    PDF (215.41KB)
  • 19 Mar 2018

    Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos® (CPX-351) outside the United States

  • 27 Feb 2018

    Half Year Results for the Six Months Ended 31 December 2017
    Related materials
    PDF (1.33MB) Presentation (pdf 2.05MB)
Our global offices
  • Australia & New Zealand
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Access cliniport

Cliniport allows healthcare professionals to source medicines and place orders in a secure and efficient environment.

Access Cliniport
Subscribe to our email alerts
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2018 Clinigen Group plc. By Emperor